NASDAQ: DMAA
Drugs Made In America Acquisition Corp Earnings Dates, Reports, Calls

Drugs Made In America Acquisition earnings were N/A for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest DMAA earnings report on Sep 30, 2025 announced Q3 2025 earnings of $2.2M, down 4.5% from last quarter.

DMAA earnings history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

DMAA Return on Equity

Insufficient data to display

DMAA Return on Assets

Insufficient data to display

Be the first to know when DMAA announces earnings.

DMAA Return on Capital Employed

Current Company
0%
Current Industry
5.7%

DMAA vs Shell Company Stocks

TickerEBITDAEarningsY/Y EarningsEPS
DMAAN/AN/AN/AN/A
KCHVN/AN/AN/AN/A
BDCIN/AN/AN/AN/A
IPCXN/AN/AN/AN/A
SOULN/AN/AN/AN/A

Drugs Made In America Acquisition Earnings Reports & History FAQ

What were Drugs Made In America Acquisition's earnings last quarter?

Drugs Made In America Acquisition (NASDAQ: DMAA) reported Q3 2025 earnings per share (EPS) of $0.07, up 450% year over year. Total DMAA earnings for the quarter were $2.18 million. In the same quarter last year, Drugs Made In America Acquisition's earnings per share (EPS) was -$0.02.

If you're new to stock investing, here's how to buy Drugs Made In America Acquisition stock.

Is Drugs Made In America Acquisition profitable or losing money?

As of the last Drugs Made In America Acquisition earnings report, Drugs Made In America Acquisition is currently losing money. Drugs Made In America Acquisition's net profit (also called net income) for the twelve months ending Sep 30, 2025 was N/A, a N/A decrease year over year.

What was DMAA's earnings growth in the past year?

As of Drugs Made In America Acquisition's earnings date in Q1 2026, Drugs Made In America Acquisition's earnings has grown year over year. DMAA earnings in the past year totalled N/A.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.